14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026
BHST vs GLPG: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 20, 2026, Galapagos NV (GLPG) is the stronger overall head-to-head candidate over BioHarvest Sciences Inc. (BHST) in the Tradestie Institutional Equity Comparison Engine, winning 9–0 core matrix metrics and 3–1 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). BHST carries a Unified Composite Score of 58.2/100 (HOLD) at $1.30 (N/M Forward P/E, -18.0% operating margin), whereas GLPG carries 61.5/100 (BUY) at $27.73 (N/M Forward P/E, 88.0% operating margin).
Technical & Structure Timing Caution: BHST is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 37.2); meanwhile GLPG is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 36.5). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on BHST vs GLPG. Trailing 12-month operating profitability (BHST -18.0% vs GLPG 88.0%) and valuation multiples (BHST N/M vs GLPG N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Packaged Foods value chain with $29.9M market capitalization and -18.0% operating margin.
OpEx & R&D Reinvestment77.0% of Rev ($27M)
90D Engineering Disclosures0 Published
GLPG Moat ProfileHigh-Margin Pricing Power Moat
Biotechnology Operator
Competes within the Biotechnology value chain with $1.9B market capitalization and 88.0% operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
Investor FAQ BHST vs GLPG Key Questions & Quantitative Answers
As of Nov 20, 2026, Galapagos NV (GLPG) is the stronger overall head-to-head candidate over BioHarvest Sciences Inc. (BHST) in the Tradestie Institutional Equity Comparison Engine, winning 9–0 core matrix metrics and 3–1 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). BHST carries a Unified Composite Score of 58.2/100 (HOLD) at $1.30 (N/M Forward P/E, -18.0% operating margin), whereas GLPG carries 61.5/100 (BUY) at $27.73 (N/M Forward P/E, 88.0% operating margin). Technical & Structure Timing Caution: BHST is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 37.2); meanwhile GLPG is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 36.5). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
GLPG leads the Growth & Scale pillar: BHST posts +3.8% YoY revenue growth and +0.0% YoY earnings growth on $35M TTM revenue (59.0% gross margin, -18.0% operating margin), compared with GLPG at +1093.2% YoY revenue growth and N/A YoY earnings growth on $602M TTM revenue (56.0% gross margin, 88.0% operating margin). On trailing 12-month operating scale, BHST generates $35M in USD-normalized revenue versus $602M for GLPG. In operating R&D and SG&A reinvestment, BHST deploys 77.0% of Rev ($27M) (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for GLPG.
BHST and GLPG trade at balanced relative valuation multiples. BHST trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 0.7x EV/Revenue (-26.6% FCF margin), whereas GLPG trades at N/M Forward P/E, 5.1x Trailing P/E, N/M PEG, and 3.2x EV/Revenue (51.1% EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against BHST (-142.5% ROE) versus GLPG (10.4% ROE) capital efficiency.
In options market volatility and institutional positioning, BHST carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.25β · 86% Vol realized risk). By comparison, GLPG carries 35.2% implied volatility (2nd %ile, Compressed (<25th %ile)), thin ADR options open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.71β · 20% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.